Evidence map›Paper›PMID 41945172›Full record

ArticleJournal of neurology2026

Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months.

Nina Gleisner, Francisco Meda, Magnus Johnsson, Igal Rosenstein, Ellen Alpsten, Lenka Novakova, Jan Lycke, Henrik Zetterberg, Hlin Kvartsberg, Brynhildur Hafsteinsdottir and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nina GleisnerDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. nina.gleisner@gu.se.ORCID http://orcid.org/0009-0000-9037-3406
Francisco MedaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Magnus JohnssonDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Igal RosensteinDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Ellen AlpstenDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Lenka NovakovaDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jan LyckeDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Hlin KvartsbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Brynhildur Hafsteinsdottir *Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Markus Axelsson *Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

the Göteborg Foundation for Neurological Research #2023-00015the Gothenburg Society of Medicine #GLS972383the Rune and Ulla Amlövs Foundation for Neurological Research #2022-358the Rune and Ulla Amlövs Foundation for Neurological Research #2023-405
6 · The paper itself

Abstract

backgroundThere is an unmet need for predictive biomarkers in Guillain-Barré syndrome (GBS). We aimed to determine whether cerebrospinal fluid (CSF) alpha-internexin (AINX) concentrations are associated with disease severity and outcome in GBS.

methodsThis retrospective cohort included 100 GBS patients. AINX concentrations were measured at diagnosis using a sensitive Simoa assay. Disease severity at nadir was assessed with the GBS Disability Scale (GBSDS) and the need for mechanical ventilation. Poor outcome was defined as GBSDS > 2 at 12 months. Logistic regression with log-transformed AINX assessed associations with severe disease at nadir (GBSDS > 2), need for mechanical ventilation, and poor outcome at 12 months (GBSDS > 2). ROC curve analysis assessed the ability of AINX to predict poor outcome and compared its performance with previously reported biomarkers re-analyzed in this cohort.

resultsAINX concentrations at diagnosis were higher in patients with poor outcome and remained associated with poor outcome after adjustment for age (OR 12.48, 95% CI 1.20-129.1, p = 0.034). This association remained significant after additional adjustment for axonal subtypes (OR 26.38, 95% CI 1.12-619.77, p = 0.042). ROC analysis demonstrated good discriminative performance (AUC of 0.79, 95% CI 0.61-0.97, p = 0.002). The optimal cutoff of 2.9 ng/L yielded 50% sensitivity and 95.7% specificity. AINX concentrations were not associated with disease severity at nadir or with need for mechanical ventilation.

conclusionsElevated CSF AINX at diagnosis was associated with poor long-term outcome in GBS, consistent with a possible contribution of CNS-related injury to recovery.

Indexed as

Guillain-Barre SyndromeIntermediate Filament ProteinsAdultAgedBiomarkersDisability EvaluationFemaleHumansMaleMiddle AgedPrognosisRespiration, ArtificialRetrospective StudiesROC CurveSeverity of Illness Indexalpha-internexinBiomarkersIntermediate Filament ProteinsAlpha-internexinBiomarkersGuillain–Barré syndromePrognosis

Identifiers

PMID41945172
PMCPMC13056748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.